Pirtobrutinib
Sign in to save this workspacePrimary targets: BTK · FDA status: FDA Approved
Selectivity scorecard
KISS
99.49
Gini
0.656
CATDS
0.024
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Pirtobrutinib. Strongest target: BTK at 97.7% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | BTK | 97.7% | 2.3% |
| 2 | ERBB4_HER4 | 95.7% | 4.3% |
| 3 | MEK2 | 89.3% | 10.7% |
| 4 | BRK | 88.1% | 11.9% |
| 5 | YES_YES1 | 82.6% | 17.4% |
| 6 | MEK1 | 81.8% | 18.2% |
| 7 | C_KIT | 69.7% | 30.3% |
| 8 | TEC | 66.9% | 33.1% |
| 9 | TXK | 65.1% | 34.9% |
| 10 | JAK2 | 63.3% | 36.7% |
| 11 | TNIK | 59.5% | 40.5% |
| 12 | LCK | 58.3% | 41.7% |
| 13 | FYN | 58.1% | 41.9% |
| 14 | CSK | 56.0% | 44.0% |
| 15 | FGR | 53.3% | 46.7% |
| 16 | FGFR1 | 52.0% | 48.0% |
| 17 | IRAK1 | 50.1% | 49.9% |
| 18 | AURORA_C | 49.7% | 50.3% |
| 19 | FGFR2 | 48.9% | 51.1% |
| 20 | FMS | 47.3% | 52.7% |
Selectivity landscape
Where Pirtobrutinib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Pirtobrutinib.
Annotations
Sign in to read and post annotations.
Loading…